Axinn Successfully Represents Alvogen Before FTC
November 3, 2015
Axinn successfully represented Alvogen before the Federal Trade Commission in connection with Alvogen’s approval to buy the divestiture products in the proposed Mylan/Perrigo transaction. Mylan’s bid for Perrigo is valued at $25 billion, and Alvogen will acquire seven separate pharmaceutical products as a result of the FTC-mandated and approved divestiture. Alvogen was also approved to acquire the divestiture products in Pfizer/Hospira earlier this year. The FTC’s Mylan press release can be found here.
The Axinn team based in Washington, DC consisted of partner Michael Keeley, assisted by associate Kenina Lee.
To subscribe to our publications, click here.
Featured Insights
Featured Insights
The Empty Chair in Antitrust Conspiracy Cases
Webinar
Antitrust
USC Gould/Analysis Group Global Competition Law Thought Leadership Conference
Speaking Engagement
Antitrust
17th ACI Summit on Biosimilars & Innovator Biologics
Speaking Engagement
Intellectual Property
GCR Live: Europe 2026
Speaking Engagement
Antitrust
20th Annual IBA Competition Mid-Year Conference
Speaking Engagement
Antitrust
Axinn Partners Named to Lawdragon 500 Leading Global Litigators 2026
News
Litigation & Trials
Turning Up the Heat: Federal Circuit Sets the Temperature for pH Measurements in Precedential Opinion
Axinn Viewpoints
Intellectual Property
Axinn Represents Tecomet in Closing of Merger with Orchid Orthopedic
Deals & Cases
Antitrust
Recent Benchmarking Suits Highlight DOJ Enforcement Risks
Byline Articles
Antitrust
“Old Crime, New Code” – DOJ Outlines its Views on When Software and AI Can Facilitate Collusion
Axinn Viewpoints
Antitrust

